ARCHIVED: High Red Blood Folate Levels Linked to Silenced Tumor-Suppressors
Study examines effects of supplementation, other factors, on gene methylation
MD Anderson News Release 12/22/2010
People with higher levels of folate in their red blood cells were more likely to have two tumor-suppressing genes shut down by methylation, a chemical off switch for genes, researchers report in the December issue of Cancer Prevention Research.
DNA hypermethylation, notes co-author Jean-Pierre Issa, M.D...
ARCHIVED: Protein Disables p53, Drives Breast Cells Toward Cancer Transition
High expression of TRIM24 is common in breast cancer, correlates with poor survival
MD Anderson News Release 12/15/10
The recently...
ARCHIVED: Alcohol and Cancer: Know Your Limit
MD Anderson Encourages Holiday Partygoers to Practice Mindful Behavior
MD Anderson News Release 12/13/2010
When raising...
ARCHIVED: Poor Breast Cancer Prognosis Associated With Presence of Circulating Tumor, Cancer Stem Cells
Research shows cells' effect on survival of metastatic breast cancer patients treated with high-dose chemotherapy and stem cell transplant
MD Anderson News Release 12/10/10
Metastatic breast cancer patients whose blood contains circulating tumor cells (CTCs) before or after treatment with high-dose chemotherapy and blood stem cell transplant have shorter survival periods, according to a new study by researchers at The...
ARCHIVED: Drugs are Safe, Active in Patients Normally Ineligible for Clinical Trial
Combination given to AML, MDS patients who have second disease and no options
MD Anderson News Release 12/10/10
A two-drug combination...
ARCHIVED: Cancer Prevention Expert Honored for Innovative Tobacco Research
National program recognizes UT MD Anderson scientist Alexander Prokhorov
MD Anderson News Release 12/09/10
Behavioral scientist...
ARCHIVED: Small Molecule May Disarm Enemy of Cancer-Fighting p53
First clinical trial looks at RG7112 as a way to disable MDM2 in leukemia
MD Anderson News Release 12/07/10
A pioneering clinical...
ARCHIVED: After 15 Years, Mendelsohn to Change Role
John Mendelsohn, M.D., who has served as president of The University of Texas
MD Anderson Cancer Center through an incredibly...
ARCHIVED: Phase I Trial Indicates Ponatinib May Thwart Most Resistant CML
Drug also acts against chronic myeloid leukemia with untreatable T315I mutation
MD Anderson News Release 12/04/10
A new drug...
ARCHIVED: UT MD Anderson Cancer Center Honors Legendary Journalist Bob Schieffer
Annual Dallas/FortWorth Fundraiser Features Interview With NBC's Tom Brokaw
MD Anderson News Release 12/03/10
HOUSTON - A Conversation...